SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-116010
Filing Date
2023-11-09
Accepted
2023-11-09 07:57:46
Documents
14
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2330299d2_8k.htm   iXBRL 8-K 25985
2 EXHIBIT 99.1 tm2330299d2_ex99-1.htm EX-99.1 11467
3 GRAPHIC tm2330299d2_ex99-1img001.jpg GRAPHIC 6604
  Complete submission text file 0001104659-23-116010.txt   224611

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA egrx-20231109.xsd EX-101.SCH 3012
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE egrx-20231109_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE egrx-20231109_pre.xml EX-101.PRE 22357
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2330299d2_8k_htm.xml XML 3325
Mailing Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677
Business Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677 201-326-5300
EAGLE PHARMACEUTICALS, INC. (Filer) CIK: 0000827871 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36306 | Film No.: 231390121
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences